Abstract
Purpose: :
To evaluate visual and anatomic outcomes in patients with serous pigment epithelial detachments treated with ranibizumab.
Methods: :
Retrospective review of medical records and diagnostic images.
Results: :
Of 231 eyes newly diagnosed with exudative age-related macular degeneration (AMD) in a six month time period, 29 (12.5%) were found to have a serous detachment of the retinal pigment epithelium (RPE). Of these 29 eyes, 24 completed six months of treatment and 3 of 24 (12.5%) developed a tear of the RPE during the first six months of treatment. Among the patients with serous detachment of the RPE treated with ranibizumab, mean visual acuity improved from 20/100 at baseline to 20/57 at the six-month time point.
Conclusions: :
Patients with serous detachment of the RPE represent a distinct subgroup of patients with exudative AMD. Although these patients have a risk of tear of the RPE and attendant limitation in vision when treated with ranibizumab, patients treated with ranibizumab had a mean improvement in vision at the six-month time point.
Keywords: age-related macular degeneration • retinal pigment epithelium • clinical (human) or epidemiologic studies: outcomes/complications